Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OriCAR-017 in Relapsed/Refractory Multiple Myeloma
NCT05016778Phase 1Unknown
- Sponsor
- Zhejiang University
- Start
- Jun 2021
- Primary completion
- Jun 2024
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of oricar-017 in multiple myeloma (MM), sponsored by Zhejiang University. Primary endpoints: Dose Limiting Toxicity at 28 days and Adverse Events and Serious Adverse Events at 2 years. Status: unknown.
02
Drugs
oricar-017
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT05016778.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05016778.